Comparative toxicity and contrast enhancing assessments of Gd2O3@BSA and MnO2@BSA nanoparticles for MR imaging of brain glioma

Abstract

The albumin-templated Gd₂O₃ and MnO₂ nanoparticles (NPs) have been developed as a new type of magnetic resonance (MR) T₁ contrast agents. However, their potential toxicity and applicability for MR imaging of brain gliomas has not been fully explored so far. In this study, we prepared Gd₂O₃@BSA and MnO₂@BSA nanoparticles (NPs) and investigated their toxicity comprehensively and comparatively by H&E staining, blood biochemical analysis, and adverse outcome pathways testing. It is revealed that both Gd₂O₃@BSA and MnO₂@BSA NPs are biocompatible at a rational dose level. Although the relaxivity of MnO₂@BSA NPs is less than that of Gd₂O₃@BSA NPs, the MnO₂@BSA NPs lead to a greater contrast enhancement in the brain glioma due to the controlled release of Mn ions under the acidic tumor microenvironmental conditions. These comparative toxicity and contrast enhancement data are of fundamental importance for the clinical translation of Gd₂O₃@BSA and MnO₂@BSA NPs as MR contrast agents for brain glioma diagnosis.

Keywords: BSA-Templated method; Brain gliomas; Gd(2)O(3) and MnO(2) nanoparticles; Magnetic resonance imaging; Toxicity.